

Correction: Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP)

Sawada H, Oeda T. Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP). *BMJ Open* 2013;3:e003533.

- 1) In the section 'Methods and analysis', subheading 'Primary outcome measure and statistical analysis,' the following sentence has a typographical error: 'Primary outcome measure is the time to the occurrence of psychosis from V2 during 48 weeks.' This should be 'Primary outcome measure is the time to the occurrence of psychosis from V2 during 96 weeks.' The study was designed as 96-week of observation period, as described elsewhere in the manuscript, and this was due to a typographical error.
- 2) In table 1 'Multiplicative Parkinson Psychosis Questionnaire score', the structure is disarranged. The corrected table 1 is below.

Table 1 Multiplicative Parkinson Psychosis Questionnaire score

Severity	Frequency		
A. Early symptoms /sleep disturbance	Up to once per week	Several times per week	Once or more per day
Not or slightly affecting well-being	1	2	3
Moderately affecting well-being	2	4	6
Severely affecting well-being	3	6	9
B. Hallucinations /illusions	Only during the night	During the night and occasionally during the day	Almost every day & night
Insight retained	1	2	3
No full insight	2	4	6
Lacking insight	3	6	9
C. Der day	Up to once per week	Several times per week	Once or more per day
Without affecting the social environment	1	2	3
Affecting the patient by emotional distress	2	4	6
Affecting the patient by accusation, aggression, or lack of cooperation	3	6	9
D. Orientation	Up to once per week	Several times per week	Once or more per day
No requirement of supervision	1	2	3
Temporal requirement of supervision	2	4	6
Permanent requirement of supervision	3	6	9

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

BMJ Open 2016;6:e003533corr1. doi:10.1136/bmjopen-2013-003533corr1



CrossMark